Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has appointed chief medical officer Dr Matthew Davis as its new chief operating officer.
With the additional role, Tiziana said Davis will further drive the company's growth and strategic initiatives under its executive chairman, founder and interim CEO Gabriele Cerrone.
The company said he will be responsible for overseeing day-to-day operations, including research and development, manufacturing, clinical trials, and commercialization efforts, noting that his extensive experience in the biotechnology industry, coupled with a deep understanding of medical affairs, will be invaluable in advancing its pipeline and achieving key milestones.
"Matthew's promotion from chief medical officer to chief operating officer is a testament to his exceptional leadership skills and his significant contributions to Tiziana Life Sciences," Cerrone said in a statement.
"His expertise in both clinical and operational aspects of the biotech industry will be instrumental in driving the company's growth and bringing our promising therapeutic candidates to patients in need.”
Tiziana said Davis has played a pivotal role in the continued development and progression of the company's therapeutic programs as chief medical officer. His strategic insights and dedication to improving patient outcomes have been instrumental in advancing the company's lead asset foralumab into a phase 2 trial in non-active secondary progressive multiple sclerosis this year and the company's mission to develop innovative treatments for various CNS diseases, it added.
"I am excited to continue to work closely with the highly talented research and development team of Drs Jules Jacobs and Vaseem Palejwala and build upon the strong foundation we have established,” Davis commented.
“Together, as a company, we will continue to drive the development and commercialization of transformative therapies that address unmet medical needs."
Tiziana is developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Contact the author at stephen.gunnion@proactiveinvestors.com